Strides Pharma Science (NSE:STAR) Debt-to-Equity : 1.18 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Strides Pharma Science Debt-to-Equity?

Strides Pharma Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹17,737 Mil. Strides Pharma Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹7,431 Mil. Strides Pharma Science's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹21,256 Mil. Strides Pharma Science's debt to equity for the quarter that ended in Mar. 2024 was 1.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Strides Pharma Science's Debt-to-Equity or its related term are showing as below:

NSE:STAR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.76 Med: 1.14 Max: 1.37
Current: 1.18

During the past 13 years, the highest Debt-to-Equity Ratio of Strides Pharma Science was 1.37. The lowest was 0.76. And the median was 1.14.

NSE:STAR's Debt-to-Equity is ranked worse than
88.3% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs NSE:STAR: 1.18

Strides Pharma Science Debt-to-Equity Historical Data

The historical data trend for Strides Pharma Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Debt-to-Equity Chart

Strides Pharma Science Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.88

0.85

1.28

1.37

1.18

Strides Pharma Science Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															1.37	N/A	1.36	N/A	1.18

Competitive Comparison of Strides Pharma Science's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strides Pharma Science's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Debt-to-Equity falls into.

Strides Pharma Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Strides Pharma Science's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17737.31	+	7431.34)	/	21255.63
	=	1.18

Strides Pharma Science's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17737.31	+	7431.34)	/	21255.63
	=	1.18

Strides Pharma Science (NSE:STAR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Strides Pharma Science Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Strides Pharma Science (NSE:STAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (NSE:STAR) » Definitions » Debt-to-Equity

Traded in Other Exchanges

532531:India

Address

Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076

Website

https://www.strides.com

Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market strategy focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Strides Pharma Science (NSE:STAR) Headlines

No Headlines